Zobrazeno 1 - 10 of 13 pro vyhledávání: '"Sara C M Stoof"'
1
Akademický článek
Optimal Dosing and Timing of High-Dose Corticosteroid Therapy in Hospitalized Patients With COVID-19: Study Protocol for a Retrospective Observational Multicenter Study (SELECT)
Autor: Katrijn Daenen, Jilske A Huijben, Anders Boyd, Lieuwe D J Bos, Sara C M Stoof, Hugo van Willigen, Diederik A M P J Gommers, Hazra S Moeniralam, Corstiaan A den Uil, Nicole P Juffermans, Merijn Kant, Abraham J Valkenburg, Janesh Pillay, David M P van Meenen, Frederique Paulus, Marcus J Schultz, Virgil A S H Dalm, Eric C M van Gorp, Janke Schinkel, Henrik Endeman
Publikováno v: JMIR Research Protocols, Vol 12, p e48183 (2023)
BackgroundIn hospitalized patients with COVID-19, the dosing and timing of corticosteroids vary widely. Low-dose dexamethasone therapy reduces mortality in patients requiring respiratory support, but it remains unclear how to treat patients when this
Externí odkaz: https://doaj.org/article/1f915a3b9dca45afacf50674f5cca22b
Zobrazit plný text záznamu
2
The one-stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non-severe haemophilia A: Superiority or non-inferiority?
Autor: Marieke J. H. A. Kruip, Luca S Hodes, Iris van Moort, Moniek P.M. de Maat, Sara C. M. Stoof, Lisette M. Schütte, Frank W.G. Leebeek, Marjon H. Cnossen
Publikováno v: Haemophilia, 26(5), 916-922. Wiley-Blackwell Publishing Ltd
Haemophilia
Introduction Diagnosis, treatment monitoring and assessment of desmopressin effect in haemophilia A patients are performed by measurement of factor VIII activity (FVIII). The two assays commonly applied are the one‐stage assay and the chromogenic a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eee7dfef38a887fd6a8e093240acaeb6
https://doi.org/10.1111/hae.14106
Zobrazit plný text záznamu
4
Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients
Autor: Reinier M. van Hest, Lisette M. Schütte, Marjon H. Cnossen, Sara C. M. Stoof, Ron A. A. Mathôt, Marieke J. H. A. Kruip, Frank W.G. Leebeek
Publikováno v: Thrombosis and Haemostasis, 118(4), 621-629. Georg Thieme Verlag
Thrombosis and haemostasis, 118(04), 621-629. Schattauer GmbH
Background Nonsevere haemophilia A (HA) patients can be treated with desmopressin. Response of factor VIII activity (FVIII:C) differs between patients and is difficult to predict. Objectives Our aims were to describe FVIII:C response after desmopress
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9d3830242f6ea353f97fa8dd77a25f6
https://doi.org/10.1160/th17-06-0390
Zobrazit plný text záznamu
6
Hemophilia B in a female with intellectual disability caused by a deletion of Xq26.3q28 encompassing the F9
Autor: Rogier Kersseboom, Anneke J.A. Kievit, Femke A. T. de Vries, Marieke J. H. A. Kruip, Frank W.G. Leebeek, Sara C. M. Stoof
Publikováno v: Molecular Genetics & Genomic Medicine
Molecular genetics & genomic medicine, 6(6), 1220-1224. John Wiley & Sons Inc.
textabstractBackground: Hemophilia B is an X-linked recessive disorder caused by mutations in the F9 on Xq27.1. Mainly males are affected but about 20% of female carriers have clotting factor IX activity below 0.40 IU/ml and bleeding problems. Fragil
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb502b5bad96671bb3d80354418e4257
https://pubmed.ncbi.nlm.nih.gov/30264515
Zobrazit plný text záznamu
7
Side effects of desmopressin in patients with bleeding disorders
Autor: F. W. G. Leebeek, M.P.M. de Maat, Sara C. M. Stoof, Marieke J. H. A. Kruip, Marjon H. Cnossen
Publikováno v: Haemophilia, 22(1), 39-45. Wiley-Blackwell Publishing Ltd
Desmopressin is frequently used in patients with bleeding disorders because of its prohaemostatic effects. In recent years desmopressin use increased due to reported high incidence of inhibitors in mild haemophilia after clotting factor infusion and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fc33d9a42668b013f3da5fd28c3b40f
https://doi.org/10.1111/hae.12732
Zobrazit plný text záznamu
8
Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey
Autor: H. W. van Steenbergen, Johannes J. Duvekot, M. Peters, Suzanne C. Cannegieter, Jeroen Eikenboom, Y.V. Sanders, Sara C. M. Stoof, Marieke J. H. A. Kruip, F. W. G. Leebeek, A. Zwagemaker
Publikováno v: Haemophilia
Haemophilia, 21(4), 505-512. Wiley-Blackwell Publishing Ltd
Haemophilia, 21(4), 505-512. Wiley-Blackwell
Haemophilia, 21(4), 505-512
Pregnant women with bleeding disorders require specialised peripartum care to prevent postpartum haemorrhage (PPH). If third trimester coagulation factor levels are = 500 mL within 24h postpartum and severe PPH as blood loss >= 1000 mL. Primary PPH w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f3c1333296057c1c104c788897b99b2
https://doi.org/10.1111/hae.12635
Zobrazit plný text záznamu
9
Desmopressin in haemophilia: The need for a standardised clinical response and individualised test regimen
Autor: Marjon H. Cnossen, Lisette M. Schütte, Marieke J. H. A. Kruip, Sara C. M. Stoof, F. W. G. Leebeek
Publikováno v: Haemophilia, 23(6), 861-867. Wiley-Blackwell Publishing Ltd
Introduction Due to interindividual variation in desmopressin response, non-severe haemophilia A patients require desmopressin testing prior to therapeutic treatment. However, adequate response or frequency of blood sampling is not standardised in in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e6dc1a521bacd88363b168fda75a52f
https://pubmed.ncbi.nlm.nih.gov/28636264
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje